About
Care and conscience are
the core of our corporate values
more
the core of our corporate values
English
We are one of the leading companies in the peripheral and neurovascular interventional medical device market in China. As a fully integrated medical device company, Zylox-Tonbridge medical has strong R&D and manufacturing capabilities, multiple specialized technology platforms, and proven commercialization capabilities. Led by our talented management team, we strive to provide best medical services and cutting-edge technical solutions to physicians and patients in China and around the world.
We are an integrated solution provider, offering the most comprehensive product solutions for peripheral and neurovascular medical devices in China. Since the establishment in 2012, we have systematically developed more than 60 quality products to adequately cover the rapidly growing neurovascular and peripheral vascular intervention market.
Zylox Medical Devices Co.,Ltd was founded in Hangzhou, China
Zylox-Tonbridge Medical Technology Co., Ltd Announces the Listing on the Main Board of the Hong Kong Stock Exchange on July 5th.
Zylox-Tonbridge IPO Stock Code: 2190
Obtained NMPA approval for four important products: Clot retriever stent (ICR), Aspiration catheter, PTA drug-coated balloon catheter (DCB), and Snare Retrieval Kit for IVC Filter. Commenced full scale production and commercialization in China.
PTA drug-coated balloon catheter (DCB) accomplished clinical trail on July.
Clot retriever stent (ICR) accomplished clinical trail on October.
Ton-Bridge Medical won Second price in Biomedical Industry Finals of the 7th China Innovation and Entrepreneurship Competition.
Zylox Medical and Ton-Bridge Medical officially merged into the current Zylox-Tonbridge Medical Technology Co, Ltd.
Zylox Medical won Second price in Biomedical Industry Finals of the 6th China Innovation and Entrepreneurship Competition.
Zhuhai Ton-Bridge Medical Tech Co., Ltd was founded in Zhuhai, China, dedicated to making and marketing high-value neurovascular intervention and implantable medical devices.
Zylox Medical's drug-coated PTA balloon dilatation catheter (PTA DCB) （"NMPA"）was awarded a "Green Channel" designation for innovative product with accelerated review process by the National Medical Products Administration ("NMPA").
Zylox Medical was awarded a "Key Enterprise Research Institute for technological innovation in vascular medical device industry" in Zhejiang Province.
Zylox Medical Devices Co.,Ltd was founded in Hangzhou, China
Zylox-Tonbridge Medical Technology Co., Ltd Announces the Listing on the Main Board of the Hong Kong Stock Exchange on July 5th.
Zylox-Tonbridge IPO Stock Code: 2190
Founder & Chairman CEO
SVP, Sales and Marketing
PhD SVP, GM of neurovascular business
CFO
VP
On the road of fulfilling our mission, we embrace enthusiasm, go beyond ourselves and keep moving forward.
We strive to provide all patients, regardless of their race, age and affluence, high quality and affordable medical products that are the fruits of medical science and technology advancement.
Care and conscience are our core corporate values. We care for every life: patients, doctors and our employees. We engage in medical business with conscience and dignity. The well-being of the patients is the utmost motivation in everything we do.
By focusing on transforming advanced technology into affordable medical products, we strive to provide reliable medical products for doctors and patients, and guard human health.
Zylox-Tonbridge Medical highlights the corporate social responsibility and mission, and boosts the innovation and technological development by taking active part in the combination of scientific innovation with medical engineering. Besides, we keep launching the professional teaching activities to the practitioners in the medical field, regulating the employees and partners to observe the high-level compliance policies and codes of ethics, performing the corporate social responsibilities, and abiding by the commitment to the shareholders and all other stakeholders.
